BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 18565875)

  • 1. The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle.
    Schimmel J; Larsen KM; Matic I; van Hagen M; Cox J; Mann M; Andersen JS; Vertegaal AC
    Mol Cell Proteomics; 2008 Nov; 7(11):2107-22. PubMed ID: 18565875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
    Bailey D; O'Hare P
    Biochem J; 2005 Dec; 392(Pt 2):271-81. PubMed ID: 16117725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUMO-2/3 conjugates accumulating under heat shock or MG132 treatment result largely from new protein synthesis.
    Castorálová M; Březinová D; Svéda M; Lipov J; Ruml T; Knejzlík Z
    Biochim Biophys Acta; 2012 Apr; 1823(4):911-9. PubMed ID: 22306003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ubiquitin-like modifier FAT10 interferes with SUMO activation.
    Aichem A; Sailer C; Ryu S; Catone N; Stankovic-Valentin N; Schmidtke G; Melchior F; Stengel F; Groettrup M
    Nat Commun; 2019 Oct; 10(1):4452. PubMed ID: 31575873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.
    González-Prieto R; Cuijpers SA; Kumar R; Hendriks IA; Vertegaal AC
    Cell Cycle; 2015; 14(12):1859-72. PubMed ID: 25895136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics analysis of nucleolar SUMO-1 target proteins upon proteasome inhibition.
    Matafora V; D'Amato A; Mori S; Blasi F; Bachi A
    Mol Cell Proteomics; 2009 Oct; 8(10):2243-55. PubMed ID: 19596686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Characterization of SUMO-SIM Interactions.
    Husnjak K; Keiten-Schmitz J; Müller S
    Methods Mol Biol; 2016; 1475():79-98. PubMed ID: 27631799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Converging Small Ubiquitin-like Modifier (SUMO) and Ubiquitin Signaling: Improved Methodology Identifies Co-modified Target Proteins.
    Cuijpers SAG; Willemstein E; Vertegaal ACO
    Mol Cell Proteomics; 2017 Dec; 16(12):2281-2295. PubMed ID: 28951443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin-dependent proteolytic control of SUMO conjugates.
    Uzunova K; Göttsche K; Miteva M; Weisshaar SR; Glanemann C; Schnellhardt M; Niessen M; Scheel H; Hofmann K; Johnson ES; Praefcke GJ; Dohmen RJ
    J Biol Chem; 2007 Nov; 282(47):34167-75. PubMed ID: 17728242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Fluorescent In Vitro Assay to Investigate Paralog-Specific SUMO Conjugation.
    Eisenhardt N; Chaugule VK; Pichler A
    Methods Mol Biol; 2016; 1475():67-78. PubMed ID: 27631798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha.
    van Hagen M; Overmeer RM; Abolvardi SS; Vertegaal AC
    Nucleic Acids Res; 2010 Apr; 38(6):1922-31. PubMed ID: 20026589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the Role of Paralog-Specific Sumoylation of HDAC1.
    Citro S; Chiocca S
    Methods Mol Biol; 2017; 1510():329-337. PubMed ID: 27761832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small ubiquitin-like modifier 3-modified proteome regulated by brain ischemia in novel small ubiquitin-like modifier transgenic mice: putative protective proteins/pathways.
    Yang W; Sheng H; Thompson JW; Zhao S; Wang L; Miao P; Liu X; Moseley MA; Paschen W
    Stroke; 2014 Apr; 45(4):1115-22. PubMed ID: 24569813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies.
    Sha Z; Blyszcz T; González-Prieto R; Vertegaal ACO; Goldberg AL
    J Biol Chem; 2019 Oct; 294(42):15218-15234. PubMed ID: 31285264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the tumor suppressor PTEN by SUMO.
    González-Santamaría J; Campagna M; Ortega-Molina A; Marcos-Villar L; de la Cruz-Herrera CF; González D; Gallego P; Lopitz-Otsoa F; Esteban M; Rodríguez MS; Serrano M; Rivas C
    Cell Death Dis; 2012 Sep; 3(9):e393. PubMed ID: 23013792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconstitution of SUMO-dependent ubiquitylation in vitro.
    Keusekotten K; Praefcke GJ
    Methods Mol Biol; 2012; 832():111-23. PubMed ID: 22350879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SUMO chains: polymeric signals.
    Vertegaal AC
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):46-9. PubMed ID: 20074033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Puromycin induces SUMO and ubiquitin redistribution upon proteasome inhibition.
    Matsumoto H; Saitoh H
    Biochem Biophys Res Commun; 2016 Jul; 476(3):153-8. PubMed ID: 27181354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arkadia/RNF111 is a SUMO-targeted ubiquitin ligase with preference for substrates marked with SUMO1-capped SUMO2/3 chain.
    Sriramachandran AM; Meyer-Teschendorf K; Pabst S; Ulrich HD; Gehring NH; Hofmann K; Praefcke GJK; Dohmen RJ
    Nat Commun; 2019 Aug; 10(1):3678. PubMed ID: 31417085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular features of human ubiquitin-like SUMO genes and their encoded proteins.
    Su HL; Li SS
    Gene; 2002 Aug; 296(1-2):65-73. PubMed ID: 12383504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.